Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extracorporeal hepatocyte-based therapy - Vital Therapies

Drug Profile

Extracorporeal hepatocyte-based therapy - Vital Therapies

Alternative Names: ELAD; Extracorporeal bio-artificial liver; VTL C3A

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vital Therapies
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver failure
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alcoholic hepatitis; Liver failure

Most Recent Events

  • 20 Sep 2018 Discontinued - Phase-II/III for Liver failure in Saudi Arabia (Extracorporeal)
  • 20 Sep 2018 Discontinued - Phase-III for Alcoholic hepatitis in Ireland, Germany, Spain, United Kingdom, Australia, Australia, USA (Extracorporeal)
  • 20 Sep 2018 Discontinued - Phase-III for Liver failure in Spain, United Kingdom, Australia, USA (Extracorporeal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top